For this phase @ , parallel , randomised , placebo-controlled trial , eligible patients were adults with advanced oesophageal cancer or type I/II Siewert junctional tumours , histologically confirmed squamous-cell carcinoma or adenocarcinoma , who had progressed after chemotherapy , with WHO performance status @-@ , and with measurable or evaluable disease on CT scan .